Amphastar Pharmaceuticals, Inc. (AMPH) Share buybacks
- Total buybacks · last 12 months (USD): Value $100.07M; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2026-06-30..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2026-06-30..
Share buybacks
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $100.07M | Trailing-year cash paid for share repurchases. Period ending 2026-06-30. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 100.07M USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2026-06-30 | $100.07M | (m) | (m) |
| 2026-03-31 | $94.08M | (m) | (m) |
| 2025-12-31 | $75.59M | (m) | (m) |
| 2025-09-30 | $97.07M | (m) | (m) |
| 2025-06-30 | $127.18M | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) |
| 2024-12-31 | $85.46M | (m) | (m) |
| 2024-09-30 | $43.46M | (m) | (m) |
| 2024-06-30 | $58.50M | (m) | (m) |
| 2023-12-31 | $58.14M | (m) | (m) |
| 2023-09-30 | $76.21M | (m) | (m) |
| 2023-06-30 | $40.71M | (m) | (m) |
| 2023-03-31 | $46.70M | (m) | (m) |
| 2022-12-31 | $39.91M | (m) | (m) |
| 2022-09-30 | $35.28M | (m) | (m) |
| 2022-06-30 | $26.88M | (m) | (m) |
| 2022-03-31 | $26.32M | (m) | (m) |
| 2021-12-31 | $28.87M | (m) | (m) |
| 2021-09-30 | $18.83M | (m) | (m) |
| 2021-06-30 | $17.06M | (m) | (m) |
| 2021-03-31 | $17.26M | (m) | (m) |
| 2020-12-31 | $24.43M | (m) | (m) |
| 2020-09-30 | $34.81M | (m) | (m) |
| 2020-06-30 | $34.91M | (m) | (m) |
| 2020-03-31 | $30.23M | (m) | (m) |
| 2019-12-31 | $22.29M | (m) | (m) |
| 2019-09-30 | $11.12M | (m) | (m) |
| 2019-06-30 | $14.29M | (m) | (m) |
| 2019-03-31 | $20.44M | (m) | (m) |
| 2018-12-31 | $25.05M | (m) | (m) |
| 2018-09-30 | $28.41M | (m) | (m) |
| 2018-06-30 | $28.42M | (m) | (m) |
| 2018-03-31 | $30.17M | (m) | (m) |
| 2017-12-31 | $30.75M | (m) | (m) |
| 2017-09-30 | $25.70M | (m) | (m) |
| 2017-06-30 | $18.90M | (m) | (m) |
| 2017-03-31 | $13.39M | (m) | (m) |
| 2016-12-31 | $9.91M | (m) | (m) |
| 2016-09-30 | $13.16M | (m) | (m) |
| 2016-06-30 | $15.34M | (m) | (m) |
| 2016-03-31 | $13.10M | (m) | (m) |
| 2015-12-31 | $9.87M | (m) | (m) |
| 2015-09-30 | $5.59M | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) |
| 2014-12-31 | $389.00K | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) |
| 2013-12-31 | $199.00K | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) |
| 2012-12-31 | $811.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |